Marissa Vignali
Research Subjects
Marissa Vignali has a total of 355 co-authors. Here are the top co-authors by number of shared publications:
- Harlan Robins
Adaptive Biotechnologies, Seattle, WA 98102, USA
27 shared publications - Ryan O. Emerson
A-Alpha Bio Inc, Data Science, Seattle, WA, USA
26 shared publications Erik C. Yusko
23 shared publications- Amy L. Popple
Institute of Cancer Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
16 shared publications - Edmund Poon
F-Star Therapeutics, Babraham Research Campus, Cambridgeshire, United Kingdom. 3
16 shared publications Eleanor J. Cheadle
16 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
Genomic intratumor heterogeneity (ITH) may be associated with postsurgical relapse of localized lung adenocarcinomas. Recently, mutations, through generation of neoantigens, were shown to alter tumor immunogenicity through T-cell responses. Here, we performed sequencing of the T-cell receptor (TCR) in 45 tumor regions from 11 localized lung adenocarcinomas and observed substantial intratumor differences in T-cell density and clonality with the majority of T-cell clones restricted to individual tumor regions. TCR ITH positively correlated with predicted neoantigen ITH, suggesting that spatial differences in the T-cell repertoire may be driven by distinct neoantigens in different tumor regions. Finally, a higher degree of TCR ITH was associated with an increased risk of postsurgical relapse and shorter disease-free survival, suggesting a potential clinical significance of T-cell repertoire heterogeneity.Significance: The present study provides insights into the ITH of the T-cell repertoire in localized lung adenocarcinomas and its potential biological and clinical impact. The results suggest that T-cell repertoire ITH may be tightly associated to genomic ITH and disease relapse. Cancer Discov; 7(10); 1088–97. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1047
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
Genomic intratumor heterogeneity (ITH) may be associated with postsurgical relapse of localized lung adenocarcinomas. Recently, mutations, through generation of neoantigens, were shown to alter tumor immunogenicity through T-cell responses. Here, we performed sequencing of the T-cell receptor (TCR) in 45 tumor regions from 11 localized lung adenocarcinomas and observed substantial intratumor differences in T-cell density and clonality with the majority of T-cell clones restricted to individual tumor regions. TCR ITH positively correlated with predicted neoantigen ITH, suggesting that spatial differences in the T-cell repertoire may be driven by distinct neoantigens in different tumor regions. Finally, a higher degree of TCR ITH was associated with an increased risk of postsurgical relapse and shorter disease-free survival, suggesting a potential clinical significance of T-cell repertoire heterogeneity.Significance: The present study provides insights into the ITH of the T-cell repertoire in localized lung adenocarcinomas and its potential biological and clinical impact. The results suggest that T-cell repertoire ITH may be tightly associated to genomic ITH and disease relapse. Cancer Discov; 7(10); 1088–97. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1047
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table from TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
Table S1. Patient demographics and characteristics.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table from TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
Table S1. Patient demographics and characteristics.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figures S1-S11 from TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
Supplemental Figure S1. Number of predicted neoantigens. Supplemental Figure S2. Association between expressed branch predicted neoantigens and relapse. Supplemental Figure S3. Substantial ITH in the number of unique T cell rearrangements. Supplemental Figure S4. Substantial ITH in tumor-enriched T cell repertoire in 8 patients whose blood samples were available. Supplemental Figure S5. A minority of T cell clones are shared between different regions within a tumor. Supplemental Figure S6. The top 5 clones within each tumor are conserved across all regions of that given tumor. Supplemental Figure S7. Tumor-enriched MOI in patients with available paired blood. Supplemental Figure S8. CD4-dominant T cell infiltrate in localized lung adenocarcinomas by immunohistochemical (IHC) staining. Supplemental Figure S9. Correlation between predicted neoantigen burden and TCR metrics. Supplemental Figure S10. Association between intratumor TCR heterogeneity and patient relapse. Supplemental Figure S11. Follow up time (months) in patients who recurred and those who have not. n.s., not significant.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figures S1-S11 from TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
Supplemental Figure S1. Number of predicted neoantigens. Supplemental Figure S2. Association between expressed branch predicted neoantigens and relapse. Supplemental Figure S3. Substantial ITH in the number of unique T cell rearrangements. Supplemental Figure S4. Substantial ITH in tumor-enriched T cell repertoire in 8 patients whose blood samples were available. Supplemental Figure S5. A minority of T cell clones are shared between different regions within a tumor. Supplemental Figure S6. The top 5 clones within each tumor are conserved across all regions of that given tumor. Supplemental Figure S7. Tumor-enriched MOI in patients with available paired blood. Supplemental Figure S8. CD4-dominant T cell infiltrate in localized lung adenocarcinomas by immunohistochemical (IHC) staining. Supplemental Figure S9. Correlation between predicted neoantigen burden and TCR metrics. Supplemental Figure S10. Association between intratumor TCR heterogeneity and patient relapse. Supplemental Figure S11. Follow up time (months) in patients who recurred and those who have not. n.s., not significant.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Data from Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Data from Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Data from Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Data from Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade